IXAZOMIB CAP,ORAL
Clinical Criteria Summary
Disease Indication & Treatment Setting
- Diagnosis of multiple myeloma with documented relapsed or progressive disease
- Use of ixazomib combination is for patient with newly diagnosed multiple myeloma
- Use of ixazomib combination is as maintenance myeloma therapy
Prior Therapy & Candidate Eligibility
- Patient is not a candidate for lenalidomide or dexamethasone therapy
- Received at least one prior therapy (that did not include ixazomib)
Laboratory Parameters
- Absolute neutrophil count (ANC) less than 1000/mm3 unless due to marrow involvement or associated with Duffy-null associated neutrophil count
- Platelet count less than 75,000/mm3 unless due to marrow involvement
Provider & Care Coordination
- Care is provided by a VA/VA Community Care hematology or oncology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
Reproductive Health & Counseling
- Pregnancy
- Lactating
- For patients who can become pregnant: Pregnancy must be excluded prior to receiving ixazomib
- For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for at least 90 days following treatment
- For patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for at least 90 days following treatment
Infection Prophylaxis
- Assess need for antiviral prophylaxis to reduce risk of herpes zoster reactivation
Drug Interactions
- Unmanageable drug-drug interaction